GlaxoSmithKline Pharmaceuticals Limited GLAXO NIFTY_MIDNSEPHARMA

Q: What is the current share price of GlaxoSmithKline Pharmaceuticals Limited (GLAXO)?

As of 2026-07-15 09:52 IST, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) trades at ₹2,460.00 on NSE. Its 52-week range is ₹2,103.20 to ₹3,171.18.

Q: What is the market capitalisation of GLAXO?

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has a market capitalisation of ₹41,673.88 Cr on NSE.

Q: What is the P/E ratio of GLAXO?

GLAXO trades at a trailing price-to-earnings (P/E) ratio of 40.23. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 18.08.

Q: Does GLAXO pay a dividend?

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) currently offers a dividend yield of 2.34%.

Q: What is the return on equity (ROE) of GLAXO?

GLAXO has a return on equity (ROE) of 45.69%. Its return on capital employed (ROCE) is 55.36%.

Q: Is GLAXO a good stock to buy?

This page provides a data-driven analysis of GlaxoSmithKline Pharmaceuticals Limited (GLAXO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - General · India

https://india-pharma.gsk.com

Company Profile ↓

₹2,460.00

-22.43% 1Y

Mkt Cap₹41,673.88 Cr

P/E40.23

P/B18.08

Div. Yield2.34%

52W High₹3,171.18

52W Low₹2,103.20

Book Value₹133.84

EPS (TTM)₹61.15

Company Overview

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 45.7%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 55.4%.

Consistent Profit Growth

Net profit has compounded at 19.3% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 27.2%.

Dividend Income

Offers a dividend yield of 2.34%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹3,807.55 Cr (+2.2% YoY); net profit ₹1,035.98 Cr.
Trailing 12 Months Year-on-year growth — revenue +2.2%, earnings +11.7%.
5-Year Trend Long-term compounding — revenue CAGR 5.7%, profit CAGR 19.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	5.68%
1 Year:	2.19%

Compounded Profit Growth

5 Years:	19.26%
1 Year:	11.69%

Stock Price Performance

1 Year:	-22.43%
6 Months:	+5.24%
3 Months:	+2.80%
1 Month:	+11.68%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 33% of range

₹2,103.20 ₹3,171.18

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)65.44 · Neutral

Price Performance

1M+11.68%

3M+2.80%

6M+5.24%

1Y-22.43%

Valuation vs Sector

P/E of 40.23 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 45.7%.
Healthy ROCE of 55.4%.
Excellent profit margin of 27.2%.
Profit CAGR of 19.3% over 5 years.
Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

40.23

Industry PE

39.97

Forward P/E

31.83

PEG Ratio

Book Value

₹133.84

Price to Book

18.08

P/S

10.73

EV/EBITDA

29.77

Dividend Yield

2.34%

Growth (CAGR)

Revenue 5Y

5.68%

Profit 5Y

19.26%

Revenue (YoY)

2.19%

Earnings (YoY)

11.69%

Profitability & Returns

ROCE

55.36%

ROE

45.69%

ROA

23.96%

Profit Margin

27.21%

Op Margin

32.77%

Gross Margin

62.66%

EPS (Latest Qtr)

₹16.40

EPS (TTM)

₹61.15

Balance Sheet & Liquidity

Debt/Equity

1.47

Quick Ratio

1.77

Current Ratio

2.03

Debt

₹33.27 Cr

Total Assets

₹4,323.87 Cr

Current Assets

₹3,607.06 Cr

Working Capital

₹1,827.96 Cr

Ownership

Promoter Holding

75.64%

Chg in Prom Hold

0.64%

FII / Inst Holding

8.55%

Chg in FII Hold

0.03%

Financial Snapshot

Enterprise Value

₹41,673.88 Cr

Total Revenue (TTM)

₹3,807.55 Cr

EBITDA

₹1,475.19 Cr

Free Cash Flow

₹848.02 Cr

Operating Cash Flow

₹903.30 Cr

Shares Outstanding

₹16.94 Cr

Gross Margin

62.66%

Payout Ratio

68.68%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GLAXO GlaxoSmithKline Pharmaceuticals Limited NIFTY_MIDNSEPHARMA	2,460.00	40.23	₹41,673.88 Cr	2.34%	55.36%	45.69%	5.68%	19.26%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,948.80	40.77	₹4.68 L Cr	0.83%	17.94%	13.74%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	7,315.50	75.61	₹1.94 L Cr	0.44%	18.96%	15.32%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,952.20	87.70	₹1.68 L Cr	0.78%	9.05%	25.79%	13.27%	20.22%
5	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	8,981.00	66.51	₹1.29 L Cr	0.23%	19.79%	20.48%	15.33%	33.34%
6	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,440.10	22.07	₹1.16 L Cr	0.90%	14.86%	11.27%	7.23%	11.45%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,137.40	22.71	₹1.14 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,494.30	21.42	₹1.14 L Cr	0.72%	28.42%	23.76%	19.10%	131.46%
9	MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA	1,099.00	99.82	₹1.07 L Cr	0.18%	12.57%	13.42%	22.37%	9.34%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	787.00 Cr	762.00 Cr	957.00 Cr	805.00 Cr	930.00 Cr	815.00 Cr	-	949.42 Cr	974.37 Cr	805.17 Cr	980.00 Cr	1,041.26 Cr	995.30 Cr
Cost of Revenue	-	-	-	-	-	-	-	359.16 Cr	351.94 Cr	287.71 Cr	-	363.82 Cr	344.00 Cr
Gross Profit	-	-	-	-	-	-	-	590.26 Cr	622.43 Cr	517.46 Cr	-	677.44 Cr	651.30 Cr
Operating Expenses	618.00 Cr	618.00 Cr	668.00 Cr	587.00 Cr	673.00 Cr	584.00 Cr	-	317.14 Cr	303.96 Cr	281.78 Cr	644.00 Cr	326.42 Cr	313.54 Cr
Operating Income	153.00 Cr	128.00 Cr	271.00 Cr	201.00 Cr	239.00 Cr	215.00 Cr	-	273.12 Cr	318.47 Cr	235.68 Cr	319.00 Cr	351.02 Cr	337.76 Cr
EBITDA	170.00 Cr	144.00 Cr	289.00 Cr	218.00 Cr	257.00 Cr	231.00 Cr	-	326.99 Cr	373.87 Cr	294.92 Cr	336.00 Cr	421.44 Cr	386.88 Cr
Interest Expense	1.00 Cr	0	0	0	1.00 Cr	0	-	9.00 L	58.00 L	42.00 L	1.00 Cr	1.19 Cr	61.00 L
Pretax Income	190.00 Cr	181.00 Cr	299.00 Cr	65.00 Cr	271.00 Cr	249.00 Cr	-	308.10 Cr	358.57 Cr	278.98 Cr	354.00 Cr	399.93 Cr	373.10 Cr
Tax Provision	57.00 Cr	48.87 Cr	80.73 Cr	19.50 Cr	75.88 Cr	67.23 Cr	-	78.22 Cr	95.70 Cr	73.97 Cr	95.58 Cr	104.31 Cr	95.24 Cr
Net Income	133.00 Cr	132.00 Cr	218.00 Cr	46.00 Cr	194.00 Cr	182.00 Cr	-	229.88 Cr	262.87 Cr	205.01 Cr	257.00 Cr	295.62 Cr	277.86 Cr
Diluted EPS	7.88	7.81	12.84	2.70	11.48	10.76	-	13.57	15.52	12.10	15.20	17.45	16.40

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	3,305.00 Cr	2,838.00 Cr	2,908.00 Cr	2,871.00 Cr	3,128.00 Cr	3,224.00 Cr	2,926.00 Cr	-	3,226.38 Cr	3,441.77 Cr	3,726.03 Cr	3,807.55 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	1,358.72 Cr	1,419.85 Cr	1,473.03 Cr	1,421.60 Cr
Gross Profit	-	-	-	-	-	-	-	-	1,867.66 Cr	2,021.92 Cr	2,253.00 Cr	2,385.95 Cr
Operating Expenses	2,672.00 Cr	2,360.00 Cr	2,489.00 Cr	2,363.00 Cr	2,527.00 Cr	2,567.00 Cr	2,327.00 Cr	-	1,119.23 Cr	1,183.44 Cr	1,138.65 Cr	1,138.38 Cr
Operating Income	608.00 Cr	453.00 Cr	393.00 Cr	470.00 Cr	552.00 Cr	574.00 Cr	519.00 Cr	-	748.43 Cr	838.49 Cr	1,114.35 Cr	1,247.57 Cr
EBITDA	633.00 Cr	478.00 Cr	420.00 Cr	508.00 Cr	601.00 Cr	657.00 Cr	598.00 Cr	-	903.98 Cr	887.67 Cr	1,327.98 Cr	1,475.19 Cr
Interest Expense	0	0	0	0	1.00 Cr	6.00 Cr	4.00 Cr	-	1.81 Cr	1.80 Cr	1.31 Cr	2.73 Cr
Pretax Income	756.00 Cr	578.00 Cr	511.00 Cr	540.00 Cr	683.00 Cr	306.00 Cr	525.00 Cr	-	836.40 Cr	816.19 Cr	1,259.88 Cr	1,406.01 Cr
Tax Provision	279.72 Cr	202.30 Cr	173.74 Cr	189.00 Cr	239.05 Cr	214.20 Cr	168.00 Cr	-	228.76 Cr	226.23 Cr	332.30 Cr	370.03 Cr
Net Income	476.00 Cr	376.00 Cr	337.00 Cr	351.00 Cr	445.00 Cr	93.00 Cr	358.00 Cr	-	610.69 Cr	589.96 Cr	927.58 Cr	1,035.98 Cr
Diluted EPS	28.12	22.20	19.88	20.70	26.29	5.50	21.14	-	36.05	34.83	54.76	61.15

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	3,216.00 Cr	3,055.00 Cr	3,004.00 Cr	3,947.00 Cr	3,911.00 Cr	3,136.00 Cr	3,115.00 Cr	-	3,326.58 Cr	3,556.62 Cr	4,108.07 Cr	4,323.87 Cr
Current Assets	-	-	-	-	-	-	-	-	2,494.26 Cr	2,798.42 Cr	3,409.88 Cr	3,607.06 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	34.94 Cr	64.17 Cr	538.85 Cr	1,102.05 Cr
Inventory	-	-	-	-	-	-	-	-	459.97 Cr	525.05 Cr	481.74 Cr	457.55 Cr
Receivables	-	-	-	-	-	-	-	-	192.38 Cr	222.06 Cr	292.55 Cr	273.11 Cr
Total Liabilities	-	-	-	-	-	-	-	-	1,585.31 Cr	1,778.98 Cr	2,156.75 Cr	2,056.45 Cr
Current Liabilities	-	-	-	-	-	-	-	-	1,326.37 Cr	1,524.95 Cr	1,905.15 Cr	1,779.10 Cr
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	3.00 Cr	2.00 Cr	2.00 Cr	1.00 Cr	1.00 Cr	0	35.00 Cr	-	15.54 Cr	18.66 Cr	9.95 Cr	33.27 Cr
Total Equity	1,829.00 Cr	2,184.00 Cr	2,007.00 Cr	2,058.00 Cr	2,139.00 Cr	1,820.00 Cr	1,478.00 Cr	-	1,741.27 Cr	1,777.64 Cr	1,951.31 Cr	2,267.41 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	16.94 Cr	16.94 Cr	16.94 Cr	16.94 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	338.00 Cr	139.00 Cr	234.00 Cr	473.00 Cr	409.00 Cr	490.00 Cr	578.00 Cr	-	484.23 Cr	582.02 Cr	1,289.90 Cr	903.30 Cr
Investing Cash Flow	180.00 Cr	499.00 Cr	301.00 Cr	-104.00 Cr	-153.00 Cr	-57.00 Cr	418.00 Cr	-	807.85 Cr	8.71 Cr	-45.80 Cr	396.98 Cr
Financing Cash Flow	-497.00 Cr	-638.00 Cr	-511.00 Cr	-307.00 Cr	-358.00 Cr	-428.00 Cr	-696.00 Cr	-	-1,543.32 Cr	-561.50 Cr	-769.42 Cr	-737.08 Cr
Capital Expenditure	-163.00 Cr	-208.00 Cr	-258.00 Cr	166.00 Cr	-243.00 Cr	-154.00 Cr	-42.00 Cr	-	-44.04 Cr	-31.22 Cr	-24.72 Cr	-55.28 Cr
Free Cash Flow	175.00 Cr	-69.00 Cr	-24.00 Cr	639.00 Cr	166.00 Cr	336.00 Cr	536.00 Cr	-	440.19 Cr	550.79 Cr	1,265.18 Cr	848.02 Cr
Net Change in Cash	21.00 Cr	-0	24.00 Cr	62.00 Cr	-102.00 Cr	6.00 Cr	300.00 Cr	-	-251.25 Cr	29.23 Cr	474.68 Cr	563.20 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	57.9%	58.7%	60.5%	62.7%
Operating Margin %	18.4%	16.0%	13.5%	16.4%	17.6%	17.8%	17.7%	-	23.2%	24.4%	29.9%	32.8%
Net Margin %	14.4%	13.2%	11.6%	12.2%	14.2%	2.9%	12.2%	-	18.9%	17.1%	24.9%	27.2%
ROE %	26.0%	17.2%	16.8%	17.1%	20.8%	5.1%	24.2%	-	35.1%	33.2%	47.5%	45.7%
ROCE %	-	-	-	-	-	-	-	-	37.4%	41.3%	50.6%	49.0%

Shareholding Pattern

Insiders

75.64%

Institutions

8.55%

Public Float

35.09%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GLAXO

Google News Mon, 13 Jul 2026

GSK Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTFBSQy1zYWxHVEQyZ1NfTzYzRnRZek1DYnNKSE9aY19xUUFUNnBJOUxGd29HNjRMNFZTY091QUNJSWxwc0s5a2VqdndlWjFWV0E?oc=5" target="_blank">GSK Stock Quote Price and Forecast</a>  <font colo…

Google News hu, 21 May 2026

GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNdXRJYnFTVXo1TE1yMGRZb0RtTnJTbnNabWdQdUhmd2VLYXpCVXhFbl9LUWNreWlnVTl4MTdoZTh0LV9sLTEtZ1dNYzNNMHRFNGNkRFZqNE5iS052QlN0U1ZXaTVJZkNuelhhRG5mdmVhNUlZd2swTDJVRU5SVXg4TVlPZEJqRWp6YkJjR3…

Google News hu, 09 Jul 2026

Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPVnBVMVduYXVkZms5YmdoS1QzWm5XZFg4NHpVWU5Jem9MOVkyZFpyaFQwQ0s3ejdVNGE3WXVOcFBXalRPT200MjFjazF4SThOcWJIS092NWpSNkx4X1ZCSU81bDJGcGI4OUFLeXdCR3I4aHhfYUVGNm9LU045eGw3UWpud2piWDl6dzVUZk…

Google News ue, 09 Jun 2026

Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion - CNBC

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPOW9vb05rR0ZGTFNPMmMxSEtma21pRTB3bUF4b3RTRFNCbVdOQ2RFYUZMakJUSTFTdFN4MllEb1c2NURoSE51M3U1SUlmVHNOMDZhQ0llZnJVaEk5VjNjQ1JVbV9ybWpjWHEtZmdZWThhYWxrQVZ3T3RSdTAxZjQtMUpjelh0d0g4cDdqTH…

Google News ue, 09 Jun 2026

Why is GSK stock sliding today? - Investing.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxObTdGMi01TzZHRmpkdHJoZ2xyZDY5ZEdMeVMxdS1VRlVaOUpQNnFwSmpLVzR3S0RKb3VrUnNhYU83cW1acEhsR2V3M0FhZWxmWkpzZHhkOFplT2o5TUJrczZaUmdXMXd0MHZJeDlBMTAxd0tTNWktODFtZVFqemw4M0VZMmM4eEJLWmFMVm…

Google News Wed, 29 Apr 2026

GSK shares slide as investors question one-off result boost - Reuters

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxQcEJkRGtIazlCU3ZSOFZ4elZHeVhwd1VpRS1xVy1qand1enpSMG10ZGlxTzBsc1E0SUxLcFNHVlJ2RU9qdTNCU0s4OWV6QlduZWYyMTczUllUb19CUUM2eFUxc21WTnkxRTRmT3NfWlRwQ0ZScXh0STBNUmVnMjJ1cGxPdnlQd2drY2U3WU…

GLAXO — Frequently Asked Questions

What is the current share price of GlaxoSmithKline Pharmaceuticals Limited (GLAXO)?

As of 2026-07-15 09:52 IST, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) trades at ₹2,460.00 on NSE. Its 52-week range is ₹2,103.20 to ₹3,171.18.

What is the market capitalisation of GLAXO?

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has a market capitalisation of ₹41,673.88 Cr on NSE.

What is the P/E ratio of GLAXO?

GLAXO trades at a trailing price-to-earnings (P/E) ratio of 40.23. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 18.08.

Does GLAXO pay a dividend?

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) currently offers a dividend yield of 2.34%.

What is the return on equity (ROE) of GLAXO?

GLAXO has a return on equity (ROE) of 45.69%. Its return on capital employed (ROCE) is 55.36%.

Is GLAXO a good stock to buy?

This page provides a data-driven analysis of GlaxoSmithKline Pharmaceuticals Limited (GLAXO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

GlaxoSmithKline Pharmaceuticals Limited GLAXO NIFTY_MIDNSEPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

GSK Stock Quote Price and Forecast - CNN

GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit? - Yahoo Finance

Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE) - Seeking Alpha

Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion - CNBC

Why is GSK stock sliding today? - Investing.com

GSK shares slide as investors question one-off result boost - Reuters

GLAXO — Frequently Asked Questions

What is the current share price of GlaxoSmithKline Pharmaceuticals Limited (GLAXO)?

What is the market capitalisation of GLAXO?

What is the P/E ratio of GLAXO?

Does GLAXO pay a dividend?

What is the return on equity (ROE) of GLAXO?

Is GLAXO a good stock to buy?

Explore More